Semanteon Capital Management LP Takes Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Semanteon Capital Management LP purchased a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,057 shares of the company's stock, valued at approximately $551,000.

Other institutional investors also recently made changes to their positions in the company. Hhlr Advisors LTD. purchased a new stake in Kiniksa Pharmaceuticals during the 1st quarter worth about $61,868,000. Millennium Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company's stock worth $11,612,000 after buying an additional 382,539 shares in the last quarter. Rubric Capital Management LP grew its holdings in shares of Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company's stock worth $45,165,000 after buying an additional 223,094 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company's stock valued at $12,398,000 after buying an additional 157,741 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. acquired a new stake in Kiniksa Pharmaceuticals during the first quarter worth approximately $3,107,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on KNSA. Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a "buy" rating and a $40.00 price target for the company. Wedbush upped their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an "outperform" rating in a research note on Tuesday, July 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $33.60.

Kiniksa Pharmaceuticals Trading Down 15.7 %

Shares of KNSA traded down $4.33 during mid-day trading on Tuesday, reaching $23.26. The company had a trading volume of 981,730 shares, compared to its average volume of 412,770. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of 219.18 and a beta of 0.33. The firm has a fifty day simple moving average of $25.70 and a 200-day simple moving average of $22.38. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $14.12 and a fifty-two week high of $28.15.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In related news, insider John F. Paolini sold 60,692 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the sale, the insider now owns 52,038 shares of the company's stock, valued at approximately $1,359,232.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the firm's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the transaction, the chief operating officer now directly owns 109,975 shares of the company's stock, valued at $2,955,028.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the business's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the transaction, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 112,692 shares of company stock valued at $2,950,315. Company insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.